生化学的にRecまたは治療のナイーブFavリスク前立腺CAを有するPtsにおけるPSAの減少のためのホワイトボタンマッシュルームサップ
局所療法後の生化学的に再発した前立腺がん患者と積極的監視を受けている前立腺がんのリスクが良好で治療未経験の患者におけるホワイトボタンマッシュルームサプリメントの無作為化第2相試験
This phase II trial studies how well white button mushroom supplement works in reducing prostate-specific antigen (PSA) levels in patients with prostate cancer that has come back (recurrent) or has favorable risk and has not undergone any therapy (therapy naive). PSA is a blood marker of prostate growth. White button mushroom supplement may affect PSA level, various parameters of immune system and levels of hormones that may have a role in prostate cancer growth.
調査の概要
状態
条件
詳細な説明
PRIMARY OBJECTIVES:
I. To assess the proportion of patients with any prostate specific antigen (PSA) reduction at 12 weeks (~3 months) in observation + white button mushroom (WBM) supplement arm and observation only arm (control arm). (Cohort 1) II. To assess relative change in PSA at 48 weeks (~12 months) from baseline with or without WBM treatment. (Cohort 2)
SECONDARY OBJECTIVES:
I. To evaluate, adverse events, PSA-response rate and time to PSA progression. (Cohort 1) II. To evaluate adverse events, time to initiation of additional therapy and progression. (Cohort 2)
EXPLORATORY OBJECTIVES:
I. To characterize the immunomodulatory effects of WBM supplement in serial blood samples. (Cohort 1) II. To assess the effect of therapy with WBM on sexual function. (Cohort 1) III. To assess the effect of WBM on Gleason grade in prostate cancer subjects on active surveillance. (Cohort 2) IV. To characterize the immunomodulatory effects of WBM supplement in serial blood samples and in tumor tissue. (Cohort 2) V. To characterize changes in cancer signaling pathways in tumor tissue after intake of WBM supplement. (Cohort 2) VI. To assess the effect of WBM supplement on sexual function. (Cohort 2)
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT I: Biochemically recurrent prostate cancer patients are randomized to 1 of 2 arms.
ARM IA: Patients receive white button mushroom extract orally (PO) twice daily (BID) on day 1. Treatment repeats every 4 weeks for cycles 1-3 then every 12 weeks for cycles 4-6 (36 weeks) in the absence of disease progression or unacceptable toxicity.
ARM IB: Patients undergo clinical observation for 12 weeks. If PSA continues to increase, patients have the option to receive the white button mushroom extract as in arm IA.
COHORT II: Therapy naive favorable risk prostate cancer patients are randomized to 1 of 2 arms.
ARM IIA: Patients receive white mushroom extract PO BID on day 1. Treatment repeats every 12 weeks for 4 cycles (48 weeks) in the absence of disease progression or unacceptable toxicity.
ARM IIB: Patients undergo active surveillance for 48 weeks.
After completion of study treatment, patients are followed up at 30 days.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
California
-
Duarte、California、アメリカ、91010
- City of Hope Medical Center
-
Glendora、California、アメリカ、91741
- City of Hope at Glendora
-
Irvine、California、アメリカ、92618
- City of Hope at Irvine Lennar
-
Rancho Cucamonga、California、アメリカ、91730
- City of Hope Rancho Cucamonga
-
Santa Monica、California、アメリカ、90404
- John Wayne Cancer Institute
-
South Pasadena、California、アメリカ、91030
- City of Hope South Pasadena
-
West Covina、California、アメリカ、91790
- City of Hope West Covina
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Documented informed consent of the participant and/or legally authorized representative
-
For therapy naive favorable risk prostate cancer (cohort 2 only): agreement to undergo baseline and 48 week prostate biopsy
-
Willing to forego non-study supplements containing mushroom for the duration of the study
-
Eastern Cooperative Oncology Group (ECOG) =< 2
-
Histologically or cytologically confirmed history of adenocarcinoma of the prostate
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: PSA failure defined as:
- PSA of >= 0.2 ng/mL that has increased above nadir following prostatectomy, OR
- PSA increase of 2.0 ng/mL above post-therapy nadir if other primary local therapy was used instead of prostatectomy
- NOTE: PSA value must be increasing based on 2 consecutive measurements taken at least 2 weeks apart
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Testosterone levels > 50 ng/dL
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Received any number of primary local therapies, defined as:
- Radical prostatectomy
- External beam radiation therapy
- Radioactive seed implantation
- Cryotherapy
- High-intensity focused ultrasound (HIFU)
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: May have received up to 24 months of neoadjuvant/adjuvant androgen deprivation therapy in conjunction with primary local therapy. Androgen deprivation therapy must have been completed > 6 months from day (D)1 of the study
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Neoadjuvant/adjuvant cytotoxic chemotherapy must have been completed > 6 months from day (D)1 of the study
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: No clinical or radiographic evidence of metastatic disease within 2 months prior to day 1 of protocol therapy. If metastatic disease is detected by positron emission tomography (PET) imaging only patients are eligible as long as no metastatic disease is noted on computed tomography (CT) scan (or magnetic resonance imaging [MRI]) and bone scan
-
THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Adenocarcinoma of the prostate diagnosed =< 12 months of protocol screening and has elected active surveillance as preferred management plan OR already on active surveillance
-
THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Clinical stage T1c-T2a as defined below:
- T1c: Tumor identified by needle biopsy found in one or both sides, but not palpable
- T2a: Tumor involves one-half of one side or less
-
THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Gleason score =< 6 (grade group 1) or Gleason 3+4 (grade group 2)
-
THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: Adequate biopsy of at least 10 biopsy cores
-
THERAPY NAIVE FAVORABLE RISK PROSTATE CANCER COHORT (COHORT 2) ONLY: No prior therapy for prostate cancer defined as:
- Local therapy including surgery , radiation or focal therapy (cryoablation, HIFU, light)
- Systemic therapy (hormonal, immunotherapy, targeted, chemotherapy). Subjects who have used 5-alpha reductase inhibitor (e.g. finasteride or dutasteride) > 6 months prior to D1 of protocol therapy will be allowed
-
Platelets > 100,000 /mm^3 (within 28 days prior to day 1 of protocol therapy)
-
Hemoglobin > 8 g/dL (within 28 days prior to day 1 of protocol therapy)
-
Aspartate aminotransferase, alanine aminotransferase, < 3 x upper limit of normal (ULN) (within 28 days prior to day 1 of protocol therapy)
-
Total bilirubin < 2 x ULN (within 28 days prior to day 1 of protocol therapy)
-
Creatinine < 2 x ULN (within 28 days prior to day 1 of protocol therapy)
Exclusion Criteria:
-
Other concomitant investigational anti-cancer therapy/ vaccines/biologics, corticosteroids with > 10 mg of prednisone equivalent dose
-
Therapy with mushroom supplements within last 3 months of randomization
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Neoadjuvant/adjuvant androgen derivation therapy lasting > 24 months or within 6 months prior to day 1 of protocol therapy
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Neoadjuvant/adjuvant chemotherapy within 6 months prior to day 1 of protocol therapy
-
BIOCHEMICALLY RECURRENT PROSTATE CANCER COHORT (COHORT 1) ONLY: Prior therapy for recurrent prostate cancer (unless given as a component of attempted curative salvage treatment including salvage radiation therapy, and completed > 6 months before day 1 of protocol therapy):
- Chemotherapy
- Androgen deprivation therapy
- Immunotherapy
- Targeted therapy
-
Known history of allergic reaction to mushrooms
-
Clinically significant uncontrolled illness
-
Active infection requiring treatment
-
Uncontrolled congestive heart failure, cardiac arrhythmia
-
History of other primary non-skin malignancy within previous 2 years unless treated with curative intent and in remission
-
Any other condition that would, in the Investigator?s judgment, contraindicate the patient?s participation in the clinical study due to safety concerns with clinical study procedures
-
Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm IA (white mushroom extract)
Patients receive white button mushroom extract PO BID on day 1. Treatment repeats every 4 weeks for cycles 1-3 then every 12 weeks for cycles 4-6 (36 weeks) in the absence of disease progression or unacceptable toxicity. |
Ancillary studies Given PO
他の名前:
|
|
アクティブコンパレータ:Arm IB (clinical observation)
Patients undergo clinical observation for 12 weeks. If PSA continues to increase, patients have the option to receive the white button mushroom extract as in arm IA. |
Ancillary studies Undergo clinical observation
他の名前:
|
|
実験的:Arm IIA (white mushroom extract)
Patients receive white mushroom extract PO BID on day 1. Treatment repeats every 12 weeks for 4 cycles (48 weeks) in the absence of disease progression or unacceptable toxicity. |
Ancillary studies Given PO
他の名前:
|
|
アクティブコンパレータ:Arm IIB (active surveillance)
Patients undergo active surveillance for 48 weeks. |
Ancillary studies Undergo active surveillance
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Prostate-specific antigen (PSA) (ng/mL) levels (Cohort 1)
時間枠:At 12 weeks
|
For continuous variables, descriptive statistics (number [n], mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided. |
At 12 weeks
|
|
Relative change in PSA (Cohort 2)
時間枠:Baseline up to 48 weeks
|
The relative difference in PSA will be measured as log (48 week PSA/baseline PSA). Undetectable PSA at 48 weeks will be coded as the low end of the lab measurement range for PSA. This measure of relative difference will be compared between the white button supplement (WBM) + active surveillance and active surveillance only patients. For continuous variables, descriptive statistics (n, mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided. |
Baseline up to 48 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of adverse events
時間枠:Up to 48 weeks
|
Will be defined per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Grade 2 serious adverse events and all grade 3-5 adverse events will be reported in the e-case report forms. Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, attribution, time of onset, probable association with the study treatment and reversibility or outcome. |
Up to 48 weeks
|
|
Proportion of patients with PSA response (Cohort 1)
時間枠:Up to 48 weeks
|
Will be defined as the sum of complete (PSA-normalization) and partial responders (PSA-partial response) vs non-responders. For continuous variables, descriptive statistics (number [n], mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided. |
Up to 48 weeks
|
|
Time to PSA progression (Cohort 1)
時間枠:Time from randomization to PSA progression, assessed up to 48 weeks
|
For continuous variables, descriptive statistics (number [n], mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided. |
Time from randomization to PSA progression, assessed up to 48 weeks
|
|
Time to initiation of additional therapy (Cohort 2)
時間枠:Baseline up to 48 weeks
|
For continuous variables, descriptive statistics (n, mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided. |
Baseline up to 48 weeks
|
|
Time to progression (Cohort 2)
時間枠:From randomization to progression, assessed up to 48 weeks
|
Will be defined as any Gleason grade 4 or 5 upon repeat biopsy or conversion from 3+4 to 4+3 or higher, prostate cancer is found in a greater number of prostate biopsy cores, prostate cancer occupies a greater extent of the prostate biopsy cores, PSA > 100 ng/mL. For continuous variables, descriptive statistics (n, mean, standard deviation, standard error, median range) will be provided. For categorical variables, patient counts and percentages will be provided. |
From randomization to progression, assessed up to 48 weeks
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in temporal levels of circulating myeloid-derived suppressor cells (MDSCs)
時間枠:Baseline to 48 weeks
|
Will be studies within the peripheral blood mononuclear cell (PBMC) compartment. Will evaluate the relative change in prostate cancer-associated MDSCs after 12 weeks of WBM supplement intake in borderline resectable pancreatic cancer patients versus in those on observation using a two group t-test. Results for cohort 1 will be confirmed by analyzing prostate cancer-associated MDSCs in cohort 2 as well (change from baseline to 48 weeks). |
Baseline to 48 weeks
|
|
Change in temporal levels of pro-/anti-inflammatory mediators
時間枠:Baseline up to 48 weeks
|
Will include cytokines/growth factors/chemokines, including IL-15 in plasma. Will evaluate the baseline correlatives and the relative role of treatment in a multivariate exploratory analysis. |
Baseline up to 48 weeks
|
|
Sexual function
時間枠:Up to 48 weeks
|
Will be evaluated by the sexual function questionnaire, including the Sexual Health Inventory for Men score. The Sexual Health Inventory for Men (SHIM) Questionnaire scoring system will be used. |
Up to 48 weeks
|
協力者と研究者
捜査官
- 主任研究者:Clayton S Lau、City of Hope Medical Center
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 19296
- P30CA033572 (米国 NIH グラント/契約)
- 19296 (その他の識別子:City of Hope Medical Center)
- NCI-2019-05587 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。